This page shows the latest CAR-Ts news and features for those working in and with pharma, biotech and healthcare.
Tmunity has focused on next-generation CAR T-therapies and technologies, and by joining Kite, will offer its pre-clinical and clinical programmes, including an ‘armoured’ CAR T technology platform. ... This has the potential to be applied to a
If Roche gets its way, Polivy will also become established as a viable alternative to CAR-Ts. ... We estimated about 150 patients were treated with CAR-T in five months.
This includes CAR-Ts from Celgene/Bluebird Bio, Celgene/Juno, J&J/Legend Biotech, a drug antibody conjugate from GSK and a bispecific antibody from Amgen.
respectively. The efficacy data looks similar on paper to the two approved CAR-Ts, though in a much larger group of patients, and BMS is also hoping to compensate for being ... Rates of serious adverse reactions in other CAR-T trials have tended to be
Those results suggest that FasT CAR19 – also known as GC007F) – could be a match clinically for already-marketed CD19 CAR-Ts from Novartis (Kymriah) and Gilead (Yescarta), but Gracell thinks its ... rival CD19-targeting CAR-Ts, plus seven days to
At the moment, Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) are the CAR-Ts that have been approved to treat DLBCL, with pivotal trials showing that they can ... In this trial, two patients who failed CAR-T
More from news
Approximately 9 fully matching, plus 33 partially matching documents found.
While ‘traditional’ therapeutics are produced in large batches for many people at once, CAR-Ts are typically manufactured in smaller – sometimes single dose – batches. ... Until recently, CAR-Ts were autologous therapies where the raw biological
year. The promise of the molecule is great, with analysts seeing it as a possible challenge to Novartis and Gilead’s CAR-T therapies. ... This means its clinical outcomes could match those seen in the CAR-Ts, but without the complexity and cost of
TALEN is now being deployed most widely in chimeric antigen receptor T cell (CAR-T) therapies, which generally involve harvesting T cells from patients, modifying them to attack tumour cells by ... Companies like Cellectis and partner Allogene are
FITC, which is not naturally present in the body, then becomes the target for CAR‐Ts expressing high affinity for FITC. ... Manufacture and supply of CAR‐T cell therapy, Kymriah, for B‐cell acute lymphoblastic leukaemia.
therapies, such as CAR-Ts Kymriah and Yescarta.
More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.
Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies. ... With CAR-Ts continuing to take centre stage as a paradigm shift in the treatment of cancer
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are ... More than 500 CAR-Ts are in development, making competition fierce. Earlier this year
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are ... Here, he explains what it was like to develop and deliver a groundbreaking CAR-T therapy
White paper: Are we prepared for the influx of CAR-Ts?. ... Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...